Completed PHASE2 INTERVENTIONAL 1-arm NCT00106002

Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer

A Phase II Study of Alimta as First Line Chemotherapy for Advanced or Metastatic Breast Cancer

Sponsor: Eli Lilly and Company

Conditions Breast Cancer Breast Neoplasms, Male Carcinoma, Ductal

Interventions pemetrexed

Updated 7 times since 2017 Last updated: May 29, 2009 Started: Apr 30, 2005 Primary completion: Dec 31, 2007 Completion: Dec 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Breast Cancer and Breast Neoplasms, Male and is currently completed. Eli Lilly and Company leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dallas, United States